Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Plans New “Seal Of Approval” For Firms That Abide By Ethics Code

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed is planning a program whereby device firms could self-certify that they follow the association's code of ethics on interactions with healthcare professionals

You may also be interested in...



Senate Committee Will Hear Device Concerns With Physician Payment Bill

The Senate Special Committee on Aging plans to hold a hearing in the coming months on a bill that would require device and drug makers to disclose financial relationships with physicians

Senate Committee Will Hear Device Concerns With Physician Payment Bill

The Senate Special Committee on Aging plans to hold a hearing in the coming months on a bill that would require device and drug makers to disclose financial relationships with physicians

AdvaMed seal of approval

Trade association announces availability of its "Code of Ethics" logo June 20. With a CEO signature indicating compliance with AdvaMed's code of ethics on interactions with healthcare professionals, device firms may license the "seal of approval" for use on websites, business cards and other marketing materials. The one-year, renewable license agreement has a series of conditions that align with the Office of Inspector General's standards on effective compliance programs (1"The Gray Sheet" March 6, 2006, p. 5)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel